| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2020-2023 |
| Base Year |
2024 |
| Forecast Period |
2025-2032 |
| Blood Plasma Market Size 2024 |
USD 34962 Million |
| Blood Plasma Market, CAGR |
10.4 % |
| Blood Plasma Market Size 2032 |
USD 77152.2 Million |
Market Overview:
The blood plasma market size was valued at USD 34962 million in 2024 and is anticipated to reach USD 77152.2 million by 2032, at a CAGR of 10.4 % during the forecast period (2024-2032).
Several key drivers are shaping the blood plasma market. The growing prevalence of immunodeficiency disorders, hemophilia, and other rare chronic conditions has led to heightened demand for plasma-derived products such as immunoglobulins, albumin, and coagulation factors. The expanding geriatric population, who are more susceptible to these conditions, further supports market growth. In addition, improvements in blood collection and processing technologies, robust government initiatives promoting voluntary plasma donation, and heightened awareness about the benefits of plasma-derived medicines are strengthening the overall demand. Pharmaceutical companies are actively investing in R&D to enhance the efficacy and safety of plasma-based therapies, which is accelerating product innovation.
Regionally, North America holds the largest share of the blood plasma market, driven by a strong healthcare infrastructure, high awareness of plasma donation, and the presence of leading plasma therapy manufacturers in the United States and Canada. Europe follows, supported by government-funded plasma collection programs, stringent regulatory standards that ensure product quality, and the presence of LGM Pharma. The Asia Pacific region is experiencing the fastest growth, propelled by rising healthcare expenditures, expanding patient pools, and increasing investments in plasma collection and processing facilities, particularly in China, Japan, and India. Latin America and the Middle East & Africa are also witnessing steady growth, spurred by improving healthcare systems and ongoing awareness campaigns on plasma donation and therapy accessibility. Key players in the market include Allergan, AbbVie Inc., GALDERMA, Pfizer Inc., GlaxoSmithKline plc, and Merz Pharma.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
Download Sample
Market Insights:
- The blood plasma market was valued at USD 34,962 million in 2024 and is expected to reach USD 77,152.2 million by 2032.
- Rising prevalence of immunodeficiency disorders, hemophilia, and rare diseases drives demand for immunoglobulins, albumin, and coagulation factors.
- Expanding geriatric population and improved disease awareness are increasing the need for plasma-derived therapies worldwide.
- Advancements in plasma collection, processing technologies, and strong government initiatives are strengthening market growth.
- Stringent regulatory standards and complex supply chains create operational challenges for manufacturers and suppliers.
- North America leads with 41% market share, followed by Europe at 32%, and Asia Pacific rapidly expanding at 19%.
- Key players such as Allergan, AbbVie Inc., GALDERMA, Pfizer Inc., GlaxoSmithKline plc, Merz Pharma, and LGM Pharma are investing in R&D and global expansion
Market Drivers:
Rising Prevalence of Chronic and Rare Diseases Increases Plasma Demand:
The blood plasma market is propelled by the increasing incidence of chronic and rare diseases such as hemophilia, primary immunodeficiency disorders, and autoimmune conditions. It faces a steady rise in patient populations requiring lifelong plasma-derived therapies. The growing awareness of treatment options has improved diagnosis rates and broadened access to advanced care. Healthcare systems now prioritize early intervention using plasma-based medicines, driving up demand for immunoglobulins, albumin, and coagulation factors. The need for safe and effective therapies intensifies the focus on plasma-derived products. It leads to greater investments in research and production infrastructure.
- For instance, Grifols manufactures more than 14 million vials of plasma medicines annually at its Clayton campus, accounting for about 40% of the company’s total global output.
Advancements in Plasma Collection and Fractionation Technology:
Innovations in plasma collection and fractionation technology support the expansion of the blood plasma market. Improved apheresis systems enable safer, higher-yield plasma collection, while automation increases efficiency in processing and reduces contamination risks. Pharmaceutical manufacturers are integrating advanced purification methods to enhance the efficacy and safety profiles of plasma-derived products. Automation and digital tracking optimize logistics, ensuring traceability from donor to recipient. These technological improvements reduce operational costs and shorten turnaround times for product delivery. It positions the market for accelerated growth and broader patient reach.
- For instance, Plasma Technologies LLC introduced a novel plasma fractionation process delivering IgG yields above 74% of the starting content in donor plasma—a significant improvement over older manufacturing methods, and this process also achieved 99.7% IgG purity and cut processing time to just 2–3 days, compared to conventional 7–10 days.
Robust Support from Government and Regulatory Initiatives:
Government policies and regulatory initiatives play a vital role in strengthening the blood plasma market. Authorities in major regions have launched awareness campaigns and incentives to encourage voluntary plasma donation. Rigorous standards for plasma collection and processing ensure product safety and consistency. Collaborative efforts among public health agencies, private stakeholders, and advocacy groups enhance plasma supply networks. Funding for research and infrastructure upgrades supports the sector’s resilience. It creates an environment where innovation and supply can keep pace with rising clinical needs.
Expanding Pharmaceutical Investments and R&D Activities:
Pharmaceutical companies drive the blood plasma market by allocating significant resources to R&D and production capacity. Firms focus on expanding their product pipelines to address emerging therapeutic needs and improve patient outcomes. Strategic mergers, acquisitions, and partnerships allow for efficient scaling of plasma supply chains. Investment in global manufacturing networks helps meet demand spikes and regional shortages. The industry’s commitment to innovation ensures a continuous flow of advanced plasma-derived medicines. It reinforces the market’s long-term growth prospects.
Market Trends:
Growing Adoption of Recombinant and Next-Generation Plasma Products:
The blood plasma market is experiencing a significant trend toward the adoption of recombinant and next-generation plasma-derived products. Pharmaceutical manufacturers are investing in biotechnological advancements to develop safer and more effective therapies for complex diseases. The shift from traditional plasma-derived proteins to recombinant alternatives reduces reliance on human donors and enhances product consistency. Innovations such as extended half-life coagulation factors and subcutaneous immunoglobulins are gaining wider clinical acceptance due to improved patient outcomes and convenience. It enables clinicians to address treatment gaps in rare and chronic disorders more effectively. Market participants are leveraging these advancements to diversify their portfolios and strengthen their competitive positions.
- Biogen’s Alprolix, a recombinant factor IX, increased the half-life by 3.8-fold compared to standard half-life products, substantially reducing injection frequency for people with hemophilia B.
Expansion of Global Plasma Collection Networks and Digital Integration:
The expansion of global plasma collection networks and digital integration represents a defining trend in the blood plasma market. Industry leaders are establishing new collection centers in emerging economies to meet growing demand and build resilient supply chains. The adoption of digital tools for donor management, traceability, and logistics has improved transparency and efficiency throughout the value chain. Stakeholders prioritize investments in mobile plasma collection units and advanced data analytics to optimize operations and respond to regional needs. It supports rapid scale-up during demand surges and public health emergencies. Strategic collaborations between healthcare providers, technology firms, and regulatory agencies are fostering a more agile and responsive market landscape.
- For instance, Grifols operated 344 plasma collection centers worldwide—including 289 in the U.S. and 55 in Europe—following the acquisition of 25 U.S.-based centers from BPL, which alone contributed an additional 1 million liters of plasma per year to its global supply.
Market Challenges Analysis:
Stringent Regulatory Environment and Supply Chain Complexity:
The blood plasma market faces significant challenges from a stringent regulatory environment and complex global supply chains. Regulatory authorities enforce strict standards for plasma collection, processing, and distribution, requiring continuous compliance and significant investment in quality assurance. Any lapses in documentation or traceability can result in costly recalls or supply disruptions. Complex international logistics for plasma transport demand specialized infrastructure and coordination, making the market vulnerable to delays and bottlenecks. The need for comprehensive screening and testing protocols further extends lead times. It places pressure on manufacturers to streamline operations without compromising safety or compliance.
Donor Recruitment Barriers and Product Pricing Pressures:
Recruiting and retaining qualified plasma donors remains a persistent challenge in the blood plasma market. Voluntary donation rates fluctuate due to socioeconomic factors, public perception, and health concerns, impacting supply reliability. The intensive screening and compensation requirements for donors increase operational costs. Pricing pressures from payers, governments, and healthcare systems constrain profit margins and limit affordability, especially in lower-income regions. The entry of alternative therapies intensifies competition for limited healthcare budgets. It compels manufacturers to innovate while managing costs and ensuring accessibility to plasma-derived therapies.
Market Opportunities:
Expansion into Emerging Markets and Untapped Regions:
The blood plasma market offers strong growth opportunities through expansion into emerging markets and untapped regions. Rapid urbanization and improving healthcare infrastructure in Asia Pacific, Latin America, and Africa create favorable conditions for establishing new plasma collection centers and distribution networks. Governments in these regions are increasing investments in healthcare and launching public awareness campaigns about plasma donation. Pharmaceutical firms can leverage local partnerships to improve access and address region-specific medical needs. The rising incidence of chronic diseases and expanding insurance coverage further boost demand for plasma-derived products. It opens new revenue streams and strengthens global market presence.
Advances in Therapeutic Applications and Product Innovation:
Ongoing advances in therapeutic applications and product innovation provide significant opportunities for the blood plasma market. Researchers are developing next-generation plasma-derived therapies for neurological disorders, autoimmune diseases, and emerging infectious diseases. Adoption of advanced purification and recombinant technologies enhances product safety, efficacy, and scalability. Collaborations between industry, academia, and clinical research organizations accelerate the development and approval of novel indications. The market can benefit from digital health tools to improve donor recruitment, traceability, and pharmacovigilance. It creates value through differentiated therapies and drives long-term market expansion.
Market Segmentation Analysis:
By Type:
The blood plasma market includes immunoglobulins, albumin, coagulation factors, and others. Immunoglobulins command the largest share due to their extensive use in managing immunodeficiency and autoimmune disorders. Albumin remains vital for volume replacement therapy and critical care settings, while coagulation factors are essential for treating hemophilia and other bleeding disorders.
- For example, Octapharma enhanced the purity and efficacy of its Albumin 25% solution by implementing advanced purification protocols; their production facilities now process and deliver albumin with endotoxin levels below 0.1 IU/mL for improved patient safety.
By Mode of Delivery:
The market is segmented into intravenous, subcutaneous, and intramuscular routes. Intravenous delivery leads the segment, offering rapid action and wide clinical adoption for acute interventions. Subcutaneous delivery is gaining popularity for chronic therapies, as it improves patient compliance and supports home-based care.
- For instance, in comparative clinical studies, 15-µg intramuscular influenza vaccine doses consistently delivered high seroconversion rates, ensuring reliable immune response against H1N1, H3N2, and B virus strains in large patient populations.
By Therapeutic Indication:
Key therapeutic indications in the blood plasma market include primary immunodeficiency, secondary immunodeficiency, hereditary angioedema, hemophilia, and various rare diseases. Rising prevalence of these conditions drives demand for plasma-derived products. Pharmaceutical manufacturers continue to expand product portfolios and develop specialized formulations to meet the needs of diverse patient populations across these indications.
Segmentations:
By Type:
- Immunoglobulins
- Albumin
- Coagulation Factors
- Protease Inhibitors
- Others
By Mode of Delivery:
- Intravenous
- Subcutaneous
- Intramuscular
By Therapeutic Indication:
- Primary Immunodeficiency
- Secondary Immunodeficiency
- Hemophilia
- Hereditary Angioedema
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Others
By Application:
- Therapeutics
- Diagnostics
- Research
By End User:
- Hospitals
- Clinics
- Blood Transfusion Centers
- Academic and Research Institutes
By Region:
- North America
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Regional Analysis:
North America and Europe:
North America holds 41% share of the blood plasma market, driven by advanced healthcare infrastructure, high plasma donation rates, and leading pharmaceutical manufacturers in the United States and Canada. The region benefits from well-developed regulatory frameworks and consistent investment in research, ensuring the timely introduction of new plasma-derived therapies. Strong collaboration among industry stakeholders, healthcare providers, and government agencies supports innovation and supply chain resilience. Europe accounts for 32% share, supported by robust government-funded plasma collection programs and high awareness of plasma therapies. The presence of key players and a unified regulatory environment facilitate market growth and product standardization.
Asia Pacific:
Asia Pacific contributes 19% share of the blood plasma market, with China, Japan, and India as primary growth engines. Rapidly expanding healthcare infrastructure, large patient pools, and government initiatives to increase plasma donation capacity fuel market advancement. Pharmaceutical investments in new collection and fractionation facilities further strengthen regional supply chains. Asia Pacific demonstrates high demand for immunoglobulins and albumin, reflecting the growing prevalence of chronic diseases and rare disorders. The region’s favorable regulatory reforms and improved reimbursement policies accelerate the uptake of advanced plasma therapies. Multinational companies are expanding local partnerships to capture untapped opportunities.
Latin America and Middle East & Africa:
Latin America and the Middle East & Africa collectively account for 8% share of the blood plasma market, supported by improving healthcare systems and rising awareness of plasma-derived treatments. Countries such as Brazil, Mexico, Saudi Arabia, and South Africa are investing in plasma collection infrastructure and public education programs to increase voluntary donation rates. Limited access in rural and remote areas presents challenges, but ongoing partnerships with global healthcare organizations are addressing these gaps. Expanding insurance coverage and targeted initiatives to improve supply chains support future market growth. The region’s steady progress reflects a growing commitment to plasma-based healthcare solutions.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Key Player Analysis:
- Allergan
- AbbVie Inc.
- GALDERMA
- Pfizer Inc.
- GlaxoSmithKline plc
- Merz Pharma (Germany)
- LGM Pharma.
- Lannett
- NorthStar Rx LLC
- Medytox
Competitive Analysis:
The blood plasma market features strong competition among leading pharmaceutical and biotechnology companies that control substantial global market share. Major players such as Allergan, AbbVie Inc., GALDERMA, Pfizer Inc., GlaxoSmithKline plc, and Merz Pharma set high standards for innovation, quality, and production capacity. LGM Pharma is expanding its footprint by investing in advanced plasma processing and supply chain capabilities. Companies focus on developing differentiated plasma-derived therapies, expanding product portfolios, and strengthening strategic partnerships to enhance market reach. Strict regulatory requirements and high entry barriers favor established firms with robust infrastructure and compliance records. Competitive strategies include R&D investments, geographic expansion, and targeted acquisitions to increase market presence. The market values technological advancements, efficient donor management, and strong relationships with healthcare providers to secure long-term growth.
Recent Developments:
- In June 2023, Lannett successfully emerged from Chapter 11 bankruptcy, restructuring its debt and starting a new phase focused on product development, especially in biosimilar insulins.
- In April 2024, NorthStar entered into a clinical supply agreement with Clarity for supplying Cu-67 SAR-bisPSMA for pivotal clinical trials.
- In July 2024, Flagship Pioneering, Partnership announced to develop up to 10 new drugs and vaccines, particularly targeting respiratory and immunology indications, with a potential value exceeding $7 billion.
Market Concentration & Characteristics:
The blood plasma market demonstrates a high degree of concentration, with a few multinational corporations controlling a significant share of global supply and production capacity. It is characterized by capital-intensive operations, strict regulatory oversight, and advanced technological requirements for collection, fractionation, and purification processes. Market leaders invest heavily in research, quality control, and supply chain management to maintain competitive advantages and ensure product safety. Barriers to entry remain substantial due to the need for specialized infrastructure and compliance with international standards. The market values innovation in plasma-derived therapies, efficient donor recruitment strategies, and expansion into emerging regions.
Report Coverage:
The research report offers an in-depth analysis based on Type, Mode of Delivery, Therapeutic Indication, Application, End User and Region. It details leading Market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current Market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven Market expansion in recent years. The report also explores Market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on Market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the Market.
Future Outlook:
- The blood plasma market will continue to benefit from rising demand for immunoglobulins, albumin, and coagulation factors for chronic and rare diseases.
- Pharmaceutical firms will invest in advanced fractionation technologies to improve product yield, purity, and safety.
- Market players will expand plasma collection networks, particularly in Asia Pacific, Latin America, and the Middle East & Africa.
- Regulatory bodies will enforce more stringent compliance and traceability standards across global supply chains.
- Industry partnerships and mergers will accelerate development of next-generation plasma-derived therapies.
- Digital health tools and data analytics will support efficient donor management, logistics, and pharmacovigilance.
- Governments and non-profit organizations will intensify public awareness campaigns to boost voluntary plasma donation rates.
- Market participants will focus on reducing operational costs and increasing affordability in lower- and middle-income regions.
- Research and clinical trials will broaden therapeutic applications of plasma products, addressing neurological and autoimmune conditions.
- Ongoing innovation and global expansion will strengthen resilience against supply disruptions and public health emergencies.
